Kevin Davies, author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, teases his keynote at the ACCC 49th Annual Meeting and Cancer Center Business Summit, where he will talk about the history of genome technology and its potential to change precision medicine.  The first FDA approval for a CRISPR therapy is imminent. But can this game-changing technology deliver safe and affordable precision medicine for patients?

Guest:

Kevin Davies, PhD, Executive Editor of The CRISPR Journal and GEN Biotechnology and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, Breakthrough: The Race for the Breast Cancer Gene, and Cracking the Genome; co-author of DNA: The Story of the Genetic Revolution.

“Rather than just adding a healthy gene to a bunch of cells in a patient and hoping that the gene can correct the disease in question, we now have tools, including CRISPR, to go in and actually surgically fix or repair the broken sequence in the DNA we have inherited…we are literally performing precision chemistry on the double helix.”

Hear Kevin speak live at the ACCC 49th Annual Meeting and Cancer Center Business Summit.

Resources:

• CRISPR-Directed Gene Editing in a Community Cancer Center
• AI's Role in Advancing Cancer Prevention Detection Diagnosis Treatment and Precision Medicine
• Precision Medicine Stewards: A Case Study from Sanford Health
• Manipulating Data to Make Precision Medicine Magic
• Eliminating Precision Medicine Disparities
• Development of a Model Precision Cancer Therapies Program in a Community Setting
• ACCESS: The First Step Toward Analyzing Precision Medicine Data